Opinion on Pharmaceuticals

Published within

« | ... | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

Altana considers divesting pharma business

Following disappointing trial results in its respiratory pipeline, a failure to secure the US approval of Alvesco, and the breakdown of its collaboration with Pfizer over Daxas, all eyes are on Altana as rumors suggest it is considering selling its drugs unit. As yet, Altana has neither confirmed nor denied the rumors, which follow a disappointing year for the company's pharmaceutical unit.

Published By Datamonitor
21 Oct 2005
CommentWire
CommentWire

Alza: a new focus on in-house development

Published By Datamonitor
06 Oct 2000
CommentWire
CommentWire

Alza: effective Concerta is hard to swallow

A new study shows that Alza's Concerta, which is already indicated in low doses for ADHD, can also treat severe ADHD in high doses. However, the news is unlikely to change Alza's strategy, since patients find Alza's pill uncomfortably large in its current highest dose, the company is likely to keep focusing on smaller doses.

Published By Datamonitor
01 Nov 2002
CommentWire
CommentWire

Alzheimer's disease: testing times for those at risk

Long-term studies have shown biomarkers to be effective in predicting those with mild cognitive impairment that will go on to develop Alzheimer's disease. Such a test could help companies developing new therapies for delaying or preventing the onset of Alzheimer's, and, by identifying the need for treatment early, could improve both drug uptake and treatment success rates.

Published By Datamonitor
07 Feb 2006
CommentWire
CommentWire

Amarin: RNA therapy results announced to attract suitors

In an effort to generate interest from potential partners in its investigational myasthenia gravis agent, EN101, Amarin has announced positive final efficacy data from an exploratory Phase IIa study. Although these promising data support a symptomatic effect, greater value could be expected if immunosuppressant activity is also demonstrated in later trials.

Published By Datamonitor
11 Jun 2009
Expert View
Expert View

Amgen and GlaxoSmithKline dominate proceedings at ECCEO-11 with Prolia presentations

Amgen's and GlaxoSmithKline's main goal at ECCEO-11 was to educate delegates regarding Prolia's unique mechanism of action and its key differentiators, such as its mode of administration and efficacy. Long-term safety data were presented in an attempt to address Phase III trial issues; however, it is unlikely that physicians will be persuaded to use Prolia as a first-line therapy in the near term.

Published By Datamonitor
06 Apr 2011
Expert View
Expert View

Amgen promotes novel offering at World Congress on Osteoporosis

The 2010 International Osteoporosis Foundation World Congress on Osteoporosis and 10th European Congress on Clinical and Economical Aspects of Osteoporosis and Osteoarthritis in May was the most important meeting of the year in the osteoporosis arena. While no new groundbreaking data for the drug were revealed, Amgen used the congress to promote its novel monoclonal antibody denosumab.

Published By Datamonitor
18 May 2010
CommentWire
CommentWire

Amgen: denosumab deal maximizes potential in tough European market

Amgen has announced that it has formed a partnership with GlaxoSmithKline to commercialize denosumab for the treatment of postmenopausal osteoporosis in Europe and emerging markets. While this partnership increases denosumab's potential in the EU, the challenge will be to convince payers that the new monoclonal antibody provides a clear clinical advantage over cheap and effective alternatives.

Published By Datamonitor
29 Jul 2009
CommentWire
CommentWire

Amgen: panitumumab speeding towards approval

The FDA has accepted Amgen's biologic license application for panitumumab and granted it priority review status. Under this designation, the regulator will decide whether or not to approve panitumumab within six months, potentially placing the drug head-to-head with ImClone/Bristol-Myers Squibb/Merck KGaA's Erbitux in the colorectal cancer market as early as the end of 2006.

Published By Datamonitor
13 Jun 2006
CommentWire
CommentWire

Amgen: positive pivotal data for Xgeva but cost may limit uptake

Phase III data show that treatment with Xgeva improved bone metastasis-free survival for advanced castrate-resistant prostate cancer patients, and the drug could now become the first therapy approved to delay the onset of metastasis. This would boost sales of Xgeva, but uptake may be restricted due to the high cost of treatment.

Published By Datamonitor
20 May 2011

« | ... | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | ... | » »|

No help is available.